Gilead Sciences Europe
📋 Case Summary
What happened ViiV Healthcare UK Ltd alleged Gilead Sciences Europe Ltd breached an undertaking given in Case AUTH/3137/12/18 by continuing to use the claim that Biktarvy (bictegravir/emtrictabine/tenofovir) was “Better tolerated than DTG [dolutegravir] – containing regimens”. The claim had been ruled in breach by the Code of Practice Appeal Board on 9 October 2019 (following an unsuccessful appeal by Gilead). Gilead was informed of the appeal outcome on 6 November 2019 and provided an undertaking dated 18 November 2019 accepting the Appeal Board’s decision. ViiV provided screenshots dated 20 November 2019 showing the claim still appeared on a UK-accessible website owned by Gilead. The complaint was also taken up in the name of the Director because the Authority was responsible for ensuring compliance with undertakings. Gilead investigated and identified similar material on password-protected health professional pages of its hiv.eu website; corrective action was taken on 22 November 20
📌 Clauses Breached
2,9